Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Antibody-Drug Conjugates Market Expected to Surge to US $30.42 Billion by 2033. The ADC market generated revenue of US$ 14.3 Billion in 2024 with leading…
Asahi Kasei Life Science Acquires License for Novel Antibody-Drug Conjugate Technology from The Noguchi Institute. The Noguchi Institute has developed this…
Asahi Kasei Life Science licenses the Noguchi Institute ADC platform to advance precision biologic therapies. The platform enables precise control of the…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Asahi Kasei Life Science licensed a novel antibody-drug conjugate technology from The Noguchi Institute that enables precise control over drug-to-antibody ratio and attachment site for single- and dual-payload ADCs. The partners will advance commercialization of ADC drug platforms including potential sub-licensing to biopharma companies and CDMOs such as Asahi Kasei subsidiary Bionova Scientific, with financial terms undisclosed.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Asahi Kasei Life Science Corporation / The Noguchi Institute (this deal) | 2026 | — | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| Novartis AG / Endocyte, Inc. | 2018 | $2.1B | 96 |
| Astellas Pharma Inc. / Seagen Inc. | 2009 | $4.5B | 95 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Servier / Agios Pharmaceuticals (oncology) | 2020 | $2.0B | 91 |
| Servier Pharmaceuticals LLC / Agios Pharmaceuticals Inc. | 2020 | $2.0B | 91 |
← Browse all deals · How we score deals
More: 2026 deals · Oncology deals